Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy

Background/Aim: Outcomes in cutaneous melanoma have improved significantly with the introduction of immune checkpoint inhibitors (ICIs). However, a subset of patients remains refractory to ICIs. Dacarbazine is a well-established chemotherapy option for melanoma, and National Institute for Health and Clinical Excellence...

Maleeha Anwar, G. Meléndez-Torres, R. Frazer · 0 citations
Review Open access Aug 2026

IUC26658-92 Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations

Abstract Background First-line immune checkpoint inhibitor (ICI)-based combinations have transformed metastatic renal cell carcinoma (mRCC) outcomes. However, the influence of patient ethnicity remains poorly characterized due to historical underreporting in major clinical trials. This study performed an ethnicity-base...

D. Khanna, T. Dey, E. Blanchard-Cavagis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.